Paul Tudor Jones's AUTL Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 46,213 shares of Autolus Therapeutics plc (AUTL) worth $63,774, representing 0.00% of the portfolio. First purchased in 2020-Q1, this medium-term investment has been held for 9 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in AUTL, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 106,653 shares. Largest reduction occurred in Q1 2026, reducing 235,900 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Autolus Therapeutics plc (AUTL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Autolus Therapeutics plc (AUTL) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -235,900 | Reduce 83.62% | 46,213 | $1.38 |
| Q4 2025 | +75,460 | Add 36.52% | 282,113 | $1.99 |
| Q3 2025 | +100,000 | Add 93.76% | 206,653 | $1.63 |
| Q2 2025 | +106,653 | New Buy | 106,653 | $2.28 |
| Q3 2021 | -13,991 | Sold Out | 0 | $0.00 |
| Q2 2021 | +13,991 | New Buy | 13,991 | $6.65 |
| Q3 2020 | -26,513 | Sold Out | 0 | $0.00 |
| Q2 2020 | -18,046 | Reduce 40.50% | 26,513 | $16.03 |
| Q1 2020 | +44,559 | New Buy | 44,559 | $5.99 |
Paul Tudor Jones's Autolus Therapeutics plc Investment FAQs
Paul Tudor Jones first purchased Autolus Therapeutics plc (AUTL) in Q1 2020, acquiring 44,559 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Autolus Therapeutics plc (AUTL) for 9 quarters since Q1 2020.
Paul Tudor Jones's largest addition to Autolus Therapeutics plc (AUTL) was in Q2 2025, adding 106,653 shares worth $243,169.
According to the latest 13F filing for Q1 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 46,213 shares of Autolus Therapeutics plc (AUTL), valued at approximately $63,774.
As of the Q1 2026 filing, Autolus Therapeutics plc (AUTL) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Autolus Therapeutics plc (AUTL) was 282,113 shares, as reported at the end of Q4 2025.